News Sentiment

QNTM sentiment intelligence

Quantum BioPharma Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.24 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-2.1% over one week, -14.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Quantum BioPharma Plans to Settle Debt

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -2.1% Price reacting lower
Trend fit Trend inactive -14.7% over four weeks
Fair value -86.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 33
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 7
GlobeNewswire 6
NewMediaWire 5
Quiver Quantitative 4
TradingView 3
Barchart.com 2
The Canadian Securities Exchange (CSE) 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 11
Regulatory and legal 6
Balance sheet 5
Capital return 4

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
The Canadian Securities Exchange (CSE) Direct company coverage

Quantum BioPharma Ltd.

Quantum BioPharma Ltd. (NASDAQ: QNTM) is a biopharmaceutical company focusing on treatments for neurodegenerative, metabolic, and alcohol misuse disorders. The company has a lead compound, Lucid-MS, for multiple sclerosis, and has spun out its unbuzzd™ OTC product to Unbuzzd Well

Tone
Positive 82/100
Event
Market update
Published
05 Jun 2026 11:39
Source
The Canadian Securities Exchange (CSE)
Bitget Direct company coverage

HUGE Stock: From FSD Pharma to Quantum BioPharma (QNTM)

The article details the rebranding of FSD Pharma Inc. to Quantum BioPharma Ltd. in August 2024, changing its stock ticker from HUGE to QNTM on NASDAQ and CSE. This transition, accompanied by a 65:1 reverse stock split, reflects the company's refined focus on neurodegenerative and

Tone
Neutral 50/100
Event
Regulatory and legal
Published
04 May 2026 17:39
Source
Bitget